Rockwell Medical, Inc. (RMTI)
NASDAQ: RMTI · Real-Time Price · USD
2.200
-0.130 (-5.58%)
At close: Nov 21, 2024, 4:00 PM
2.220
+0.020 (0.91%)
After-hours: Nov 21, 2024, 4:42 PM EST

Company Description

Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide.

Also, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers.

The company’s hemodialysis concentrate products are used to sustain patient’s life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream.

The company serves to hemodialysis clinics. Rockwell Medical, Inc. was formerly known as Rockwell Medical Technologies, Inc. and changed its name to Rockwell Medical, Inc. in June 2012.

Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

Rockwell Medical, Inc.
Rockwell Medical logo
Country United States
Founded 1994
IPO Date Jan 27, 1998
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 237
CEO Mark Strobeck

Contact Details

Address:
30142 South Wixom road
Wixom, Michigan 48393
United States
Phone 248 960 9009
Website rockwellmed.com

Stock Details

Ticker Symbol RMTI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001041024
CUSIP Number 774374300
ISIN Number US7743743004
Employer ID 38-3317208
SIC Code 2834

Key Executives

Name Position
Dr. Mark Strobeck Ph.D. President, Chief Executive Officer and Director
Jesse Neri Senior Vice President of Finance
Megan C. Timmins Executive Vice President, Chief Legal Officer and Secretary
Timothy T. Chole Senior Vice President and Chief Commercial Officer
Heather R. Hunter Senior Vice President and Chief Corporate Affairs Officer

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 8-K Current Report
Nov 13, 2024 424B5 Filing
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Nov 12, 2024 8-K Current Report
Oct 21, 2024 EFFECT Notice of Effectiveness
Oct 15, 2024 UPLOAD Filing
Oct 8, 2024 S-8 Securities to be offered to employees in employee benefit plans
Oct 8, 2024 S-3 Registration statement under Securities Act of 1933